Chimerix reported financial results and provided a corporate update for the second quarter ended June 30, 2016

“We believe that the results of our ongoing development program for brincidofovir have demonstrated clear clinical evidence of its potent antiviral activity against three important DNA viruses: smallpox, cytomegalovirus, and adenovirus. We are continuing to increase our understanding of brincidofovir’s antiviral potential in each of these areas and are actively pursuing trial designs that will provide a clear regulatory path forward for brincidofovir,” said M. Michelle Berrey, MD, MPH, President and CEO of Chimerix.

“We also remain committed to understanding the potential broad spectrum efficacy of brincidofovir against other viruses, such as BK virus, and will soon be in clinical testing of a promising intravenous formulation that we believe will address the gastrointestinal side effects that affected outcomes in the Phase 3 SUPPRESS trial for prevention of CMV in hematopoietic cell transplant recipients. We are also investigating alternative formulations of brincidofovir for long-term use in the solid organ transplant setting. With the patent life for brincidofovir extending until 2034 and our strong cash position, we believe it is critical to progress these efforts while continuing to work closely with both U.S. and EU regulators.”

Program Updates:

Brincidofovir for Adenovirus

In May, Chimerix provided topline results from an interim analysis of the AdVise study that showed a strong antiviral effect, correlated with overall survival, in patients treated with brincidofovir. Results of the AdVise study demonstrated the potent antiviral activity of brincidofovir in patients with life-threatening adenovirus infection, suppressing levels in the blood to undetectable in more than 80 percent of pediatric subjects. This effect was observed even among those whose immune system had not yet rebounded following their stem cell transplant. Rapid virologic response (99 percent decline or below the limit of detection at week four) was correlated with improved survival to 24 weeks after initiation of brincidofovir in both adult and pediatric subjects with disseminated disease.

Additional 24 week data results from the AdVise study will be presented October 26-30 at IDWeek in New Orleans, LA. Chimerix has also been conducting data analyses to identify risk factors that are associated with poor outcomes and mortality.

“The AdVise study was the largest clinical study ever conducted in patients with serious adenovirus infections, and we are proud to be advancing development in the field as the first company to attempt to treat this life-threatening condition. We see firsthand the clear unmet need in this area from continued demand of approximately one patient per day for brincidofovir through our Expanded Access trial and Named Patient Program in the U.S. and EU,” said Garrett Nichols, MD, MS, Chief Medical Officer at Chimerix.

The Company also announced that it is discussing the design of an additional comparative trial in patients with serious adenovirus infection to support a potential regulatory application, with the U.S. Food and Drug Administration (FDA) and European regulators, and will provide further guidance regarding trial initiation upon completion of the trial design.

“As we look ahead to continued research of brincidofovir in adenovirus, we are pleased that the European Commission granted orphan drug designation for brincidofovir for the treatment of adenovirus,” Dr. Nichols added. Companies that obtain orphan designation benefit from a number of incentives in the European Union, including scientific advice specific for designated orphan medicines and market exclusivity for 10 years with an additional two years for medicines that have complied with an agreed pediatric investigation plan.

Investigation of New Brincidofovir Formulations

Chimerix continues to advance its intravenous (IV) formulation of brincidofovir, and expects to initiate a first-in-human study during the second half of 2016 to establish target exposure levels and safety data. Chimerix plans to apply these data to develop IV brincidofovir as a potential candidate for the prevention of cytomegalovirus (CMV) and other viruses after hematopoietic cell transplantation, and the treatment of BK virus and CMV after solid organ transplantation. Preclinical results to date have demonstrated the potential for IV brincidofovir to decrease the gastrointestinal side effects observed with orally-administered brincidofovir, when administered early after stem cell transplant.

The Company is also exploring other novel formulations to enable potential longer-term use in the solid organ transplant setting.

Brincidofovir for Smallpox

The development of brincidofovir for smallpox continues, in collaboration with the Biomedical Advanced Research and Development Authority (BARDA). Upon completion of the second animal efficacy study of brincidofovir in a smallpox model, the Company plans to meet with the FDA to discuss any additional required data for a regulatory decision for brincidofovir for the treatment of smallpox. Chimerix has provided regulators with information regarding the safety and tolerability of a short course of brincidofovir oral tablets as intended for use as a medical countermeasure in the event of a smallpox bioterror attack.

Second Quarter 2016 Financial Results

Net loss decreased to $18.1 million, or $0.39 per basic and diluted share, for the second quarter of 2016 compared to a net loss of $24.8 million, or $0.59 per basic and diluted share during the same period in 2015.

Revenues for the second quarter of 2016 decreased to $1.8 million compared to $4.1 million for the same period in 2015. A portion of the revenue during these periods related to reimbursable expenses associated with the Company’s ongoing development contract with BARDA and in 2015 revenues also included $1.5 million of deferred revenue related to the Company’s collaboration and license agreement with ContraVir Pharmaceuticals.

Research and development expenses decreased to $13.8 million for the second quarter of 2016, compared to $21.9 million for the same period in 2015. This decrease was primarily due to a decrease in the Company’s clinical trial expenses with the completion of the Phase 3 SUPPRESS and AdVise trials and close-out of the kidney trials, partially offset by an increase in costs related to the development of the IV formulation of brincidofovir and the Expanded Access Program.

General and administrative expenses decreased to $6.6 million for the second quarter of 2016, compared to $7.2 million for the same period in 2015. The decrease was primarily due to a decrease in commercialization expense.

Loss from operations was $18.5 million for the second quarter of 2016, compared to a loss from operations of $25.0 million for the same period in 2015. The decreased loss was primarily due to lower research and development expenses, and general and administrative expenses, as previously discussed.

Chimerix’s balance sheet at June 30, 2016 included $301.5 million of capital available to fund operations, no debt, and approximately 46.2 million outstanding shares of common stock.

About Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel antivirals in areas of high unmet medical need. Chimerix’s proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates, including CMX669. Chimerix is also advancing a clinical candidate for norovirus infection, CMX521.

CHIMERIX, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
(unaudited)
		June 30, 2016				December 31, 2015
ASSETS
Current assets:
Cash and cash equivalents		$	32,060			$	20,605
Short-term investments, available-for-sale		240,755				199,729
Accounts receivable		313				2,432
Prepaid expenses and other current assets		4,761				6,071
Total current assets		277,889				228,837
Long-term investments		29,802				124,040
Property and equipment, net of accumulated depreciation		3,020				3,045
Other long-term assets		93				70
Total assets		$	310,804			$	355,992
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable		$	4,217			$	10,458
Accrued liabilities		6,311				9,721
Total current liabilities		10,528				20,179
Deferred rent		306				354
Total liabilities		10,834				20,533
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized at June 30, 2016 and December 31, 2015; no shares issued and outstanding as of June 30, 2016 and December 31, 2015		—				—
Common stock, $0.001 par value, 200,000,000 shares authorized at June 30, 2016 and December 31, 2015; 46,214,895 and 46,162,525 shares issued and outstanding as of June 30, 2016 and December 31, 2015, respectively		46				46
Additional paid-in capital		684,015				675,591
Accumulated other comprehensive loss, net		(269		)		(764		)
Accumulated deficit		(383,822		)		(339,414		)
Total stockholders’ equity		299,970				335,459
Total liabilities and stockholders’ equity		$	310,804			$	355,992

CHIMERIX, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share data)
(unaudited)
		Three Months Ended June 30,								Six Months Ended June 30,
		2016				2015				2016				2015
Revenues:
Contract revenue		$	1,841			$	2,598			$	3,069			$	3,833
Collaboration and licensing revenue		—				1,545				—				1,548
Total revenues		1,841				4,143				3,069				5,381
Operating expenses:
Research and development		13,759				21,860				34,695				39,365
General and administrative		6,607				7,234				13,531				13,295
Total operating expenses		20,366				29,094				48,226				52,660
Loss from operations		(18,525		)		(24,951		)		(45,157		)		(47,279		)
Interest income, net		377				136				749				199
Net loss		(18,148		)		(24,815		)		(44,408		)		(47,080		)
Other comprehensive loss:
Unrealized gain on investments, net		75				1,144				496				1,769
Comprehensive loss		$	(18,073	)		$	(23,671	)		$	(43,912	)		$	(45,311	)
Per share information:
Net loss, basic and diluted		$	(0.39	)		$	(0.59	)		$	(0.96	)		$	(1.13	)
Weighted-average shares outstanding, basic and diluted		46,214,086				42,079,716				46,199,110				41,614,494